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is suggested that mortalin/Hsp70 levels in blood be examined as prognostic markers in 
other cancer types. 
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Mitochondrial mortalin and cytosolic Hsp70 are essential chaperones 
overexpressed in cancer cells. Our goals were to reproduce our earlier findings of elevated 
circulating levels of mortalin and Hsp70 in colorectal cancer (CRC) patients with a larger 
patient cohort, to compare death risk assessment of mortalin, Hsp70, CEA and C19-9 and 
to assess their prognostic value in various CRC stages. Mortalin, Hsp70, CEA and CA19-9 
levels were determined in sera of 235 CRC patients enrolled in the study and followed-up 
5 years after surgery. Association between their concentrations and patients’ survival was 
analyzed by Kaplan-Meier estimator and subjected to Cox Proportional hazards analysis. 
Serum level of mortalin was independent of that of Hsp70, CEA and CA19-9, whereas 
Hsp70 level weakly correlated with CEA and CA19-9 levels. Improved short-term survival 
was found in early or advanced disease stages associated with lower mortalin and Hsp70 
levels. Cox regression analysis showed a high mortality hazard (HR=3.7, P<0.001) in 
patients with both high mortalin and Hsp70 circulating levels. Multivariate analysis 
showed that high mortalin and Hsp70 significantly enhances risk score over a baseline 
model of age, number of affected lymph nodes, CEA, CA19-9, disease stage and 
perioperative therapy. Analysis of mortalin and Hsp70 in CRC patients’ sera adds a high 
prognostic value to TNM stage and to CEA and CA19-9 and identifies patients with a 
lower or higher survival probability in all CRC stages. Determination of mortalin and 
Hsp70 in blood could be a useful additive prognostic tool in guiding clinical management 
of patients. 
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The heat shock proteins family (HSP) is composed of evolutionary conserved stress 
proteins and chaperones that play numerous roles in cell growth, homeostasis and stress 
response 1. Family members are involved in cancer proliferation, invasion and metastasis2-
5. Two of the HSPs are presented here: the cytoplasmic heat shock protein 70 (Hsp70)6 and 
the mitochondrial stress 70 protein (mortalin, GRP75) 7-9. Cytoplasmic Hsp70 supports 
proper folding of misfolded proteins, assembly of protein complexes, protein trafficking 
and inhibition of death promoting proteins10,11. It confers protection from various 
stressogenic factors and conditions such as reactive oxygen species, toxins, hypoxia, 
hyperthermia and others5. Mortalin plays a major role in import and refolding of 
mitochondrial proteins 7-9. It protects cells from glucose deprivation and ROS 
accumulation 12 and from serum deprivation 13 and blocks apoptosis induction via p53 14. It 
also promotes tumorigenesis 15. In contrast, knock down of mortalin caused senescence-
like growth arrest in immortalized cells 16. The main cellular location of mortalin is in 
mitochondria, yet it was described also in other cellular compartments17. Hsp7018 and 
mortalin19,20 play a role in protection of cancer cells from complement-dependent 
cytotoxicity. Following complement attack, both Hsp7018 and mortalin 19 appear on the 
surface of the targeted cells. Under non-lytic conditions, mortalin relocates rapidly from 
mitochondria to the cell surface 21 and is also shed out from the cells 20,19,22. Release of 
cytosolic Hsp70 from cells in a well-known phenomenon 23. 
Cytoplasmic Hsp70 is overexpressed in cancer and this is correlated with 
accelerated proliferation, aggressiveness and chemoresistance2,24,25. Thus, elevated 
expression of Hsp70 is a marker for advanced disease and poor prognosis in colon cancer, 
breast cancer, melanoma and bladder cancer4,5. In a prospective study, baseline serum 
concentration of soluble Hsp70 was associated with an increased risk of lung cancer 26. 
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Plasma level of soluble Hsp70 was found to be a potential biomarker for small cell lung 
cancer and prostate cancer, although its clinical utility is still undefined27,28. Extracellular 
soluble Hsp70 was also identified in blood plasma of patients with colorectal cancer 29, and 
was found to be a stage-independent prognostic marker in colorectal cancer, especially in 
patients without distant metastasis. These findings were reproduced recently with a larger 
group of CRC patients (Gráf et al., manuscript in preparation). 
Mortalin is also overexpressed in cancer15,30. Thus, in human colorectal 
adenocarcinoma, higher mortalin expression in the cancer cells correlates with poor patient 
survival 31. Elevated expression of mortalin in gastric cancer is associated with deeper 
invasion and more metastases 32. In our earlier study performed on 175 colorectal 
carcinoma (CRC) patients, a higher concentration of soluble mortalin in blood serum was 
found to correlate with shorter patients' survival33. Serum levels of mortalin and cytosolic 
Hsp70 were found to be independent variables in these patients. Concurrence of high 
mortalin and high Hsp70in the CRC patients’ sera was associated with a rapid mortality 33. 
Here, this study was repeated with a larger cohort of independent CRC patients and 
extended to include measurements of CEA, and CA19-9 levels. As shown here, serum 
levels of mortalin, CEA and CA19-9 vary in patients independently. CRC patients with 
high mortalin and high Hsp70 in their serum have a poor prognosis, irrespective of their 
cancer stage. Importantly, multivariate analysis indicated that determination of mortalin 
and Hsp70 levels in CRC patients’ sera is adding a high prognostic value to the TNM stage 
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Material and Methods 
 
Patients, pathology and serum samples 
235 patients diagnosed with colorectal cancer were involved in the study between 
January 2011 and June 2013 in the oncology ward of the 3rd Department of Internal 
Medicine, Semmelweis University. The study was carried out at the 3rd Department of 
Internal Medicine, Semmelweis University, Budapest, based on a study protocol approved 
by the Hungarian Medical Research Council Scientific and Research Committee and by the 
ethical committee of Tel Aviv University, Tel Aviv. Patients were consented consecutively 
after confirmation of invasive colorectal cancer with any stage, then clinical data and blood 
samples were collected before commencing therapy. Clinical data and blood samples were 
taken after 6 hours of fasting between 8 and 10 am by antecubital venipuncture into native, 
EDTA, or sodium citrate anticoagulated tubes before starting any anticancer therapy, were 
aliquoted and stored at -700C for further analysis. Baseline demographic and clinical 
characteristics of patients are summarized in Table 1. After diagnosis and adequate 
surgery, patients were treated and followed in the oncology ward according to the stage of 
their disease and to the current guidelines. Patients with locally advanced rectal cancer 
(cT3 or N+ disease) received radiochemotherapy before definitive surgery. Patients who 
were offered postoperative chemotherapy by a multidisciplinary tumor board decision 
received 6 month adjuvant chemotherapy starting 4-6 weeks after surgery. Twenty-two 
patients who had unresectable and/or metastatic disease received upfront primary systemic 
treatment without definitive surgery. Lymphovascular and/or venous invasion (LVI) and 
perineural invasion (PNI) were assessed by a qualified pathologist and included in the 
routine pathological report. Vascular invasion was regarded positive when tumor cells 
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were detected in the lumen of any peritumoral vein or lymphatic vessel. These indicative 
findings are referred together as LVI. PNI was indicated as positive when tumor cells were 
seen in circular fashion around any peritumoral nerve. During follow-up of at least 5 years, 
overall survival data was collected.  
 
Mortalin and Hsp70 ELISA 
The capture ELISA used for measuring serum levels of mortalin was described 
earlier33. Briefly, microtiter plate wells (Thermo Fisher Scientific, Rochester, NY) were 
coated overnight at 40C with 1 mg/ml mouse monoclonal antibody directed to human 
mortalin (Abcam) in TB (50 mM Tris Base pH 7.0, 100 mM NaCl). Following blocking of 
the wells with bovine serum albumin in TBS for 1 h at 37°C, diluted CRC patients’ serum 
samples (diluted 1:3 in Tris buffer saline) were added to the wells. Next, the wells were 
washed with TBT (TB with 0.05% Tween-20) and treated with a goat anti-mortalin 
polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) diluted in TB for 1 h at 
37°C. Finally, after a wash with TBT, peroxidase-conjugated donkey anti-goat IgG 
(Jackson ImmunoResearch Laboratories, West Grove, PA) diluted in TB was added for 1 h 
at 25°C.  Antibody binding was quantified by using TMB One Component Microwell 
Substrate (SouthernBiotech, Birmingham, AL) and absorbance was read at 450 nm in a 
Microplate Reader (Spectrafluor plus, Tecan, Austria). In each ELISA test plate, a linear 
calibration of increasing mortalin concentrations was performed with normal human serum 
supplemented with 0-2.5 ng recombinant mortalin 34. Normal human serum without added 
mortalin gave no signal above background controls. Furthermore, the signal observed with 
normal human serum was not affected by pre-adsorption of the serum over an affinity 
column bearing anti-mortalin antibodies. Soluble Hsp70 levels in the serum were measured 
using the ELISA kit of R&D Systems (Minneapolis, MN,USA), according to the 
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manufacturer’s instructions as described earlier 29. Serum Hsp70 levels in healthy 
individuals (median, 25-75 percentile) were determined in our two earlier studies. Young 
(non-pregnant) women had 0.29 (0.20-0.35) ng/ml serum Hsp7035 and healthy adults had 
0.59 (0.43-0.89) ng/ml serum Hsp7036.  
 
Statistical analysis 
Statistical analysis was performed using the SPSS 15.0 software (SPSS Inc., 
Chicago, IL). Patients’ survival was tested by the Kaplan-Meier survival analysis, using 
the Log Rank test. The impact of various variables on patients’ survival was tested by the 
Cox Proportional hazards analysis (univariate and multivariate analyses). The results of the 
Cox regression models are presented as hazard ratios, the corresponding 95% confidence 




The levels of mortalin were determined in the sera of the patients. Mortalin 
concentration varied in the sera of this cohort of CRC patients between 0-7,753 ng/ml with 
a median value of 30 ng/ml. Hsp70, CEA and CA19-9 levels were determined in our recent 
study (Gráf et al., manuscript in preparation). Spearman’s rank correlation coefficient 
analysis showed that serum levels of mortalin in the patients did not correlate with the 
Hsp70, CEA and CA19-9 levels (Table S1). Serum levels of Hsp70 (median value 1.65 
ng/ml) showed modest, but significant correlation with CEA (r=0.19; P=0.005) and CA19-
9 (r=0.21; P=0.002) levels. CEA and CA19-9 showed a good correlation (r=0.48; P<0.001) 
in these patients. The Chi-squared distribution of serum Hsp70 and mortalin levels among 
CRC stages I-IV was also examined. A weak correlation was observed between Hsp70 
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levels and CRC stages (P=0.013) and no correlation between mortalin levels and CRC 
stages (P=0.236) (Table S2).  
Records of lymphatic vascular invasion (LVI) and perineural invasion (PNI) were 
also analyzed. By using the Mann-Whitney U Test, the distribution of circulating Hsp70 
and mortalin levels were compared between patients with negative and positive LVI or 
PNI. No correlation was found between Hsp70 levels (P=0.065; P=0.353) or mortalin 
levels (P=0.844; P=0.660) and LVI or PNI (respectively). 
Kaplan Meier survival analysis of the patients in stage I, stage II, Stage III and 
stage IV (Figure 1A) showed the clear expected correlation between stage and the death of 
the patients during follow-up after therapy (Log Rank (Mantel-Cox): stage II, P=0.063; 
stage III, P=0.008; stage IV, P<0.001, when compared to stage I). Analysis of patients 
with low (≤30 ng/ml) vs. high (>30 ng/ml) mortalin level in serum during the follow-up, 
gave a Log Rank overall comparison of P<0.05 between the two groups (Figure 1B). In the 
Kaplan Meier survival analysis shown in Figure 1C, the patients were divided into 4 
groups according to mortalin and Hsp70 levels: patients with low mortalin and Hsp70 
(Low/Low), patients with low mortalin and high Hsp70 (Low/High), patients with high 
mortalin and low Hsp70 (High/Low) and patients with high mortalin and Hsp70 
(High/High). Survival of the Low/Low patients was much better than the Low/High 
(P=0.002), High/Low (P=0.01) and High/High (P<0.001) patients. Cox regression analysis 
of the 4 sub-groups of patients according to mortalin and Hsp70 also supported the 
observation that having high Hsp70 and/or mortalin (>median values) is associated with 
faster disease progression (Table 2). Thus, High/High patients had a hazard of 3.7 (95% CI 
1.85-7.35, P<0.001) relative to Low/Low patients. 
Sub-dividing the patients according to their stages (Figure 2), showed that having a 
High/High mortalin/Hsp70 phenotype was a worse prognosis for all. Regarding early 
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stages, 3 stage I/II CRC patients with high mortalin and high Hsp70 (out of 15 patients 
with high/high phenotype) survived less than a year despite surgery and conventional 
therapy whereas all patients with low mortalin and low Hsp70 (26 patients with low/low 
phenotype) survived at least 2 years (Fig. 2 and Table S3). In Stage III patients, after 6 
years, 100% of Low/Low patients survived but only 52% of the patients who had either 
high mortalin or Hsp70 or both survived. In Stage IV patients, after 6 years, 40% of 
Low/Low patients survived but only 8% of the patients who had either high mortalin or 
Hsp70 or both survived. 
Univariate analysis by Cox regression of the variables of the patients: sex, age, 
grade and stage of the disease as well as serum CEA, CA19_9, mortalin and Hsp70 
concentrations are presented in Table 3. Only patients without missing data were included 
in this analysis (n=207-231). Age was found to be a highly significant factor with a hazard 
of 1.04 (P<0.001). High Hsp70 serum concentration (>1.65 ng/ml) was associated with 
mortality with a HR of 1.92 (P<0.001). High mortalin level (>30 ng/ml) was also found to 
be a significant factor (P=0.04) with a hazard ratio of 1.53. 
 Multivariate analysis of the risk of mortality was performed on 185 patients for 
whom all information was available. The added value of high Hsp70 and high mortalin to a 
baseline model of age, CEA, CA19-9, TNM staging and systemic perioperative therapy 
was analyzed. It significantly (P<0.001) increased the hazard ratio to 4.8 (95% CI 2.10-
11.18) (Table 4). We conclude that analysis of mortalin and Hsp70 in CRC patients’ sera 
adds a high prognostic value to the TNM staging and to the levels of CEA and CA19-9 and 
will identify colorectal cancer patients at low risk as well as high risk of short survival.  
 
Discussion 
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Colorectal cancer patients were shown to have circulating soluble mortalin and 
Hsp70 in their blood29,33. In earlier studies, we demonstrated that patients with high levels 
of Hsp70 and/or mortalin are at risk of shorter survival33. The results shown here reinforce 
this claim in a second larger cohort of colorectal patients and compares their prognostic 
strength with that of tumor stage, grade and traditional tumor markers such as CEA and 
CA19_9. Importantly, the concentrations of Hsp70, CEA and CA19-9 distributed 
differently from mortalin in patients’ sera, thus allowing testing of prognosis based on their 
combined expression. Univariate Cox regression analysis confirmed that the four variables 
were significant prognostic markers of mortality. 
To detect Hsp70, this study utilized an assay that was optimized and validated for the 
detection of free, circulating Hsp7029. More recently, a novel assay was developed to 
detect both free Hsp70 and Hsp70 bound to lipid vesicles (lipHsp70 ELISA) 37. It will be 
interesting to examine if the findings reported here may be reproduced with a novel 
lipHsp70 ELISA. The latter assay was recently used to show in non-small cell lung cancer 
patients a positive correlation between tumor volume and serum Hsp70. 38. Tumor volume 
was not measured in the CRC patients described here, but lymphatic vascular invasion and 
perineural invasion were recorded. No correlation was found between Hsp70 or mortalin 
levels and the extent of LVI or PNI. 
Survival curves clearly demonstrated that above-median concentrations of either 
mortalin or Hsp70 categorizes colorectal cancer patients as patients at risk of shorter 
survival. This is even more pronounced when both mortalin and Hsp70 are elevated. 
Strikingly, percent surviving patients after 4 years was ~50% in the High/High patients 
group and ~80% in the Low/Low patients group. Analysis of the added value of 
measurements of mortalin and Hsp70 concentrations in blood serum on top of the clinical 
value of the conventional tests extensively performed in the clinics (Table 4) is 
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demonstrating unequivocally that identification of patients with high mortalin and high 
mortalin is essential since their risk of mortality is much increased (HR= 4.84, 2.10-11.18, 
P<0.001). 
An important conclusion from our findings (Figure 2) is that determinations of 
mortalin and Hsp70 concentrations in blood may be an extremely valuable non-invasive 
test for assessment and management of both early stage and advanced stage colorectal 
cancer patients. Kaplan-Meier curves (Figure 2) and Cox regression analyses (not shown) 
of survival of early stage patients clearly demonstrate that stages I and II patients with the 
High/High phenotype should be regarded as high risk and may require adjuvant treatment, 
similar to Stage III and stage II traditionally high risk patients. In our last cohort of CRC 
patients, 3 out of 15 patients with High/High phenotype died within 3 years. In contrast, for 
stages III and IV CRC patients, having a Low/Low mortalin/Hsp70 phenotype is clearly 
indicative of longer survival times. Thus, 5 years after their operation, all 17 ‘Low/Low’ 
stage III CRC patients were alive, whereas 25 of the other 48 stage III patients have died. 
Collectively, the findings presented in this and our earlier report 33, strongly indicate that 
measurements of mortalin and Hsp70 levels in serum of CRC patients have an important 
added value for clinical management of these patients. 
It still remains to be tested whether or not high mortalin and/or high Hsp70 in serum 
are predictive markers to one or more of the prevailing therapeutic strategies. Since CRC is 
a prevalent cause of death from cancer, the impact of any novel and effective predictive 
marker will likely have a major impact on cancer death. Clearly39 , this is a priority area for 
future research on CRC and on cancer at large. Several circulating proteins have been 
proposed as diagnostic, predictive and prognostic biomarkers for CRC, including CEA, 
CA19-9, p53 and VEGF39-42. We propose that for the benefit of successful precision cancer 
therapy, mortalin and Hsp70 should be considered and examined as predictive biomarkers 
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to assess success of conventional, targeted- and immuno-therapies in early and advanced 
metastatic CRC. This will enable identification beforehand of patients who are going to 
benefit from each therapy. The source for circulating mortalin and Hsp70 is still not clear. 
They are known to be released in vitro from cells undergoing stress. In the cancer patients, 
they may originate from the cancer cells and/or from affected organs and tissues. Future 
research will have to determine whether, besides being biomarkers, circulating mortalin 
and Hsp70 have any impact on tumor progression and through which mechanism. 
Nowadays, cellular chaperones are considered major targets for cancer therapy and 
numerous targeted therapies are under development4,11. Treatment modalities targeting the 
chaperones at the protein level will have to take into account the circulating levels of these 
chaperones that will likely affect their therapeutic efficacy. 
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Table 1. CRC patients enrolled in the study. 
Number of patients   235 
Males/females: 139   139/96 
Age (mean)    66.6 
Tumor localization (N, %) 
Right colon   44 (18.7) 
Colon transversum  17 (7.2) 
Left colon   89 (37.9) 
Rectum   84 (35.7) 
Unknown   1 (0.5) 
Tumor stage (MAC) 
A    9 
B1/2/3    37/58/1 
C1/C2    10/57 
D    50 
Unknown   13 
Tumor stage (TNM) 
I    46 
II    59 
III    67 
IV    50 
Unknown   13 
Tumor grade (N, %) 
1    51 (21.7) 
2    113 (48.1) 
3    45 (19.1) 
Unknown   26 (11.1) 
Surgery (N, %) 
Definitive surgery  212 (90) 
No surgery   23 (10) 
Adjuvant chemotherapy and/or neoadjuvant chemoradiotherapy 
Stage I    17/46 
Stage II   29/59 
Stage III   60/67 
Chemotherapy for metastatic disease (at least one line) 44/50 
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Table 2. Univariate Cox proportional hazard ratio of mortality in patients with high 
mortalin and/or Hsp70 in serum relative to patients with Low/Low.  
 
Mortalin/Hsp70 * Significance (P) Hazard ratio 
95.0% confidence interval 
Lower Upper 
Low/High 0.003 2.754 1.408 5.384 
High/Low 0.018 2.293 1.156 4.550 
High/High <0.001 3.689 1.852 7.350 
 





Table 3. Univariate Cox-regression analysis: Association between sex, age of patients, 
cancer grade or stage and CEA, CA19_9, Hsp70 or mortalin serum levels and colorectal 
cancer patients’ survival. 
 
Variable*  Significance (P) Hazard Ratio 
95.0% confidence interval 
Lower Upper 
Sex 0.664 1.095 .726 1.653 
Age <0.001 1.039 1.019 1.060 
Grade 2 0.191 1.492 0.819 2.719 
Grade 3 0.103 1.789 0.889 3.599 
Stage III 0.012 3.160 1.286 7.762 
Stage IV <0.001 14.939 6.306 35.388 
CEA <0.001 3.014 1.947 4.665 
CA19_9 0.007 1.859 1.185 2.917 
Hsp70 0.002 1.924 1.279 2.892 
Mortalin 0.041 1.533 1.018 2.307 
 
* Age (years); Sex (female/male); Grade (grade 2 or 3 vs. 1, yes/no); Stage (stage III or IV 
vs. I+II, yes/no); CEA (high: >2.5 µg/ml, low: ≤2.5 µg/ml); CA19-9 (high:>8.8 units/ml, 
low: ≤8.8 units/ml); Hsp70 (high: >1.65 ng/ml, low: ≤1.65 ng/ml); Mortalin (high: >30 
ng/ml, low: ≤30 ng/ml). 
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Table 4. Multivariate Cox-regression analysis: Association between age, TNM staging, 
cancer stage, mode of systemic therapy and CEA, CA19_9, Hsp70 or mortalin serum 
levels and colorectal cancer patients’ survival 
 
 
* Age at diagnosis (years); CA19-9 (high:>8.8 units/ml, low: ≤8.8 units/ml); CEA (high: 
>2.5 µg/ml, low: ≤2.5 µg/ml); Stage (stage III or IV vs. I+II, yes/no); Therapy (adjuvant, 
metastatic first line therapy, neoadjuvant, adjuvant plus neoadjuvant, vs. no systemic 
therapy); Hsp70 (H: >1.65 ng/ml, L: ≤1.65 ng/ml); Mortalin (H: > 30 ng/ml, L: ≤30 
ng/ml). 
  
Variable * Significance (P) Hazard Ratio 
95.0% confidence interval 
Lower Upper 
Age at diagnosis 0.070 1.025 0.998 1.052 
CA19_9 0.519 0.820 0.449 1.498 
CEA 0.001 3.075 1.592 5.937 
Stage <0.001    
Stage III <0.001 6.519 2.792 15.223 
Stage IV <0.001 23.448 7.701 71.396 
No systemic therapy 0.002    
Adjuvant therapy <0.001 0.171 0.072 0.404 
Metastatic first line therapy 0.026 0.283 0.093 0.860 
Neoadjuvant therapy 0.292 0.492 0.131 1.842 
Adjuvant and neoadjuvant therapy 0.374 0.479 0.094 2.430 
MortL&Hsp70L 0.001    
MortH&Hsp70L <0.001 5.287 2.265 12.343 
MortL &Hsp70H 0.001 4.689 1.951 11.269 
MortH &Hsp70H <0.001 4.845 2.101 11.176 
Page 15 of 22
John Wiley & Sons, Inc.
International Journal of Cancer
This article is protected by copyright. All rights reserved.
16 
 
Legends to Figures 
Figure 1. Survival (Kaplan-Meier) of colorectal cancer patients. (A) Patients divided 
according to stages I-IV of disease. (B) Patients divided according to mortalin level in their 
serum; high (≥30 ng/ml) or low (<30 ng/ml). Log Rank overall comparison showed 
significant equality of survival distribution (P=0.042). (C) Patients divided according to 
their mortalin (low: ≤30 ng/ml, high: >30 ng/ml) and Hsp70 (low: <≤1.65 ng/ml, high: 
>1.65 ng/ml) levels. Patients sub-divided into Low/Low (blue), High/ Low (green), 
Low/High (beige) and High/High (purple) levels of mortalin/Hsp70 in their sera. Number 
of patients (survivors/all) and significance of difference between survival curves of High 
and Low (B, C) or High/High and Low/Low (D) patients are shown. 
 
Figure 2. Survival (Kaplan-Meier) of stage I (A), stage II (B), stage III (C) and stage IV 
(D) colorectal cancer patients. Patients divided according to their mortalin (low: ≤30 
ng/ml, high: >30 ng/ml) and Hsp70 (low: ≤1.65 ng/ml, high: >1.65 ng/ml) levels. Patients 
sub-divided into Low/Low (blue), High/ Low (green), Low/High (beige) and High/High 
(purple) levels of mortalin/Hsp70 levels in their sera. Number of patients (survivors/all) 
and significance of difference between survival curves of High/High and Low/Low 
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